Journal of Nuclear Medicine September 2024, jnumed.124.267489; DOI: https://doi.org/10.2967/jnumed.124.267489 ...
Journal of Nuclear Medicine September 2024, jnumed.124.268797; DOI: https://doi.org/10.2967/jnumed.124.268797 ...
Journal of Nuclear Medicine September 2024, jnumed.124.268011; DOI: https://doi.org/10.2967/jnumed.124.268011 ...
Journal of Nuclear Medicine September 2024, jnumed.124.268151; DOI: https://doi.org/10.2967/jnumed.124.268151 ...
Journal of Nuclear Medicine September 2024, jnumed.124.268145; DOI: https://doi.org/10.2967/jnumed.124.268145 ...
Journal of Nuclear Medicine September 2024, jnumed.124.267964; DOI: https://doi.org/10.2967/jnumed.124.267964 ...
Efficacy and Toxicity of [177 Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data ...
No CN patients had thrombocytopenia of > grade 4 while 5.8% of MAP patients had thrombocytopenia of >grade 4 (table1). 11.7% MAP patients had anemia of >grade 4, whereas 11.1 % CN patients developed ...
Journal of Nuclear Medicine September 2024, jnumed.124.267751; DOI: https://doi.org/10.2967/jnumed.124.267751 ...
Journal of Nuclear Medicine September 2024, jnumed.124.267624; DOI: https://doi.org/10.2967/jnumed.124.267624 ...
Journal of Nuclear Medicine September 2024, jnumed.124.267578; DOI: https://doi.org/10.2967/jnumed.124.267578 ...
You do not have access to the full text of this article, the first page of the PDF of this article appears above. This article requires a subscription to view the full text. If you have a subscription ...